for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lannett Company, Inc.

LCI.N

Latest Trade

13.80USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.34

 - 

15.37

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
13.80
Open
--
Volume
--
3M AVG Volume
45.35
Today's High
--
Today's Low
--
52 Week High
15.37
52 Week Low
3.34
Shares Out (MIL)
40.41
Market Cap (MIL)
557.60
Forward P/E
10.99
Dividend (Yield %)
--

Next Event

Q1 2020 Lannett Company Inc Earnings Release

Latest Developments

More

Lannett Enters Into Distribution Agreement For Posaconazole Delayed-Release Tablets

Lannett Comments On Agreement With Sinotherapeutics

Lannett Company Posts Q4 Adjusted Earnings Per Share of $0.37

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lannett Company, Inc.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Industry

Biotechnology & Drugs

Contact Info

9000 State Rd

+1.215.3339000

http://www.lannett.com/

Executive Leadership

Patrick G. LePore

Independent Chairman of the Board

Timothy C Crew

Chief Executive Officer, Director

John Kozlowski

Chief Financial Officer, Vice President - Finance

John M. Abt

Vice President and Chief Quality and Operations Officer

Maureen M. Cavanaugh

Senior Vice President and Chief Commercial Operations Officer

Key Stats

3.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.6K

2018

0.7K

2019

0.7K

2020(E)

0.5K
EPS (USD)

2017

2.860

2018

3.100

2019

2.350

2020(E)

1.256
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.85
Price To Book (MRQ)
1.57
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
218.25
LT Debt To Equity (MRQ)
198.24
Return on Investment (TTM)
-22.82
Return on Equity (TTM)
-19.70

Latest News

BRIEF-Lannett Receives FDA Approval For Dronabinol Capsules

* LANNETT COMPANY INC - RECEIVED APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR DRONABINOL CAPSULES USP, 2.5 MG, 5 MG AND 10 MG

BRIEF-Lannett Reports Q3 Adjusted Earnings Per Share $0.80

* LANNETT ANNOUNCES FISCAL 2018 THIRD-QUARTER FINANCIAL RESULTS

BRIEF-Lannett Acquires Portfolio Of Generic Products From Endo International

* LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL

BRIEF-Lannett Appoints Patrick Lepore Chairman Of Board

* LEPORE WILL SUCCEED JEFFREY FARBER, WHO WILL REMAIN A MEMBER OF BOARD Source text for Eikon: Further company coverage:

BRIEF-Lannett Company Files For Potential Mixed Shelf Offering

* LANNETT COMPANY INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2GblSC4) Further company coverage:

BRIEF-Lannett Co Reports Q2 Earnings Per Share $0.37

* LANNETT ANNOUNCES FISCAL 2018 SECOND-QUARTER FINANCIAL RESULTS; REPORTS RECORD REVENUES, STRONG EARNINGS

BRIEF-Lannett Co Voluntarily Pays Down $25 Mln Of Term Loans

* LANNETT COMPANY SAYS $25 MILLION PAY DOWN OF TERM LOANS WILL SAVE CO ABOUT $1.7 MILLION IN ANNUALIZED CASH INTEREST EXPENSE, AT CURRENT RATES Source text for Eikon: Further company coverage:

BRIEF-Lannett Enters Into Consulting Agreement With Former CEO, Bedrosian

* LANNETT ENTERS INTO CONSULTING AGREEMENT WITH FORMER CEO, ARTHUR BEDROSIAN

BRIEF-Lannett Names Timothy Crew To Board Of Directors

* LANNETT COMPANY INC - WITH CREW'S APPOINTMENT, TOTAL NUMBER OF DIRECTORS IS SEVEN Source text for Eikon: Further company coverage:

BRIEF-Lannett Appoints Timothy Crew As CEO

* LANNETT COMPANY INC - TIMOTHY CREW WILL SUCCEED ARTHUR BEDROSIAN, WHO WILL CONTINUE TO SERVE AS CEO UNTIL CREW JOINS COMPANY

BRIEF-Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution

* LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT

BRIEF-Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL

* LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®

BRIEF-Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

* Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

BRIEF-Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing

* Deerfield Management LP reports a 8.28 percent passive stake in Lannett Company Inc as of October 25, 2017-SEC filing Source text : ( http://bit.ly/2zi8xIn ) Further company coverage:

BRIEF-Lannett Co calls price fixing allegations about a single product named in complaint that co sells "meritless"

* Lannett Company Inc - comments on amended civil generic drug price-fixing complaint

BRIEF-Lannett and Celgene enter into settlement and license agreement related to Thalomid

* Lannett and Celgene enter into settlement and license agreement related to Thalomid

BRIEF-Lannett receives two FDA approvals for Lansoprazole, one each for full prescription and OTC

* Lannett receives two fda approvals for Lansoprazole delayed-release capsules usp, one each for full prescription and OTC

BRIEF-Lannett receives FDA approval for Oxycodone and Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg

* Lannett receives FDA approval for Oxycodone And Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg

BRIEF-Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg

* Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg

BRIEF-Lannett announces dismissal of class action lawsuit

* Lannett Company - judge dismissed in entirety putative class action lawsuit against a multitude of generic drug manufacturers including Lannett Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up